AR055203A1 - Derivados de benzotiofeno con propiedades antipsicoticas - Google Patents

Derivados de benzotiofeno con propiedades antipsicoticas

Info

Publication number
AR055203A1
AR055203A1 ARP060103780A ARP060103780A AR055203A1 AR 055203 A1 AR055203 A1 AR 055203A1 AR P060103780 A ARP060103780 A AR P060103780A AR P060103780 A ARP060103780 A AR P060103780A AR 055203 A1 AR055203 A1 AR 055203A1
Authority
AR
Argentina
Prior art keywords
group
alkyl
substituent
lower alkyl
alkyl group
Prior art date
Application number
ARP060103780A
Other languages
English (en)
Inventor
Hiroshi Yamashita
Hideaki Kuroda
Nobuaki Ito
Shin Miyamura
Kunio Oshima
J Matsubara
Haruka Takahashi
Tae Fukushima
Satoshi Shimizu
Kazumi Kondo
Yohji Sakurai
Takeshi Kuroda
Shinichi Taira
Motohiro Itotani
Tatsuyoshi Tanaka
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of AR055203A1 publication Critical patent/AR055203A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

El compuesto de la presente posee un amplio espectro de tratamiento para desordenes mentales que incluyen desordenes del sistema nervioso central, ningun efecto colateral y elevada seguridad. Reivindicacion 1: Un compuesto heterocíclico o una sal del mismo representado por la formula [1], donde R2 representa un átomo de hidrogeno o un alquilo inferior; A representa un grupo alquileno inferior o un grupo alquenileno inferior; y R1 representa un grupo aromático o un grupo heterocíclico seleccionado del grupo que consiste de (I) a (IV) a continuacion: (I) un grupo cicloalquilo C3-8; (II) un grupo aromático seleccionado de un grupo fenilo, un grupo naftilo, un grupo dihidroindenilo y un grupo tetrahidronaftilo; (III) un grupo heteromonocíclico saturado o no saturado que posee 1 a 4 heteroátomos seleccionado del grupo que consiste de un átomo de nitrogeno, un átomo de oxígeno y un átomo de azufre; y (IV) un grupo heterocíclico fusionado a benceno que posee 1 a 4 heteroátomos seleccionados del grupo que consiste de un átomo de nitrogeno, un átomo de oxígeno y un átomo de azufre y es seleccionado del grupo que consiste de (1) un grupo tetrahidroquinoxalinilo, (2) un grupo tetrahidroquinazolinilo, (3) un grupo dihidroquinazolinilo, (4) un grupo indolinilo, (5) un grupo indolilo, (6) un grupo isoindolinilo, (7) un grupo benzimidazolinilo, (8) un grupo dihidrobenzimidazolinilo, (9) un grupo tetrahidrobenzoazepinilo, (10) un grupo tetrahidrobenzodiazepinilo, (11) un grupo hexahidrobenzazocinilo, (12) un grupo dihidrobenzoxazinilo, (13) un grupo dihidrobenzoxazolilo, (14) un grupo benzisoxazolilo, (15) un grupo benzoxadiazolilo, (16) un grupo tetrahidrobenzoxazepinilo, (17) un grupo dihidrobenzotiazinilo, (18) un grupo benzotiazolilo, (19) un grupo benzoxatiolilo, (20) un grupo cromenilo, (21) un grupo dihidrobenzofurilo, (22) un grupo carbazolilo, (23) un grupo dibenzofurilo y (24) un grupo quinoxalinilo en donde por lo menos un grupo seleccionado del grupo que consiste de los grupos (1) al (66) a continuacion puede estar presente como substituyente en el grupo cicloalquilo C3-8, el grupo aromático y el grupo heterocíclico representado por R1: (1) un grupo alquilo inferior, (2) un grupo alquenilo inferior, (3) un grupo alquilo inferior substituido por halogeno, (4) un grupo alcoxilo inferior, (5) un grupo ariloxilo inferior, (6) un grupo alquiltio inferior, (7) un grupo alcoxilo inferior substituido por halogeno, (8) un grupo hidroxilo, (9) un grupo hidroxilo protegido, (10) un grupo hidroxialquilo inferior, (11) un grupo hidroxialquilo inferior protegido, (12) un átomo de halogeno, (13) un grupo ciano, (14) un grupo arilo, (15) un grupo nitro, (16) un grupo amino, (17) un grupo amino que tiene un grupo seleccionado del grupo que consiste de un grupo alquilo inferior, un grupo alcanoilo inferior, un grupo alcoxicarbonilo inferior, un grupo alquilsulfonilo inferior, un grupo aminocarbamoilo inferior, un grupo carbamoilalquilo inferior, un grupo alcanoilamino inferior, un grupo alcanoilo inferior alcanoilamino inferior y alcanoilo inferior carbonilaminoalcoxilo inferior como substituyente, (18) un grupo alcanoiloinferior, (19) un grupo arilsulfonilo que puede tener un grupo alquilo inferior en el grupo arilo group, (20) un grupo carboxilo, (21) un grupo alcoxicarbonilo inferior, (22) un grupo carboxialquilo inferior, (23) un grupo alquilo inferior alcoxicarbonilo inferior, (24) un grupo alcanoilo inferior alcanoilamino inferior, (25) un grupo carboxialquenilo inferior, (26) un grupo alquenilo inferior alcoxicarbonilo inferior, (27) un grupo carbamoilalquenilo inferior que puede tener un grupo seleccionado del grupo que consiste de un grupo alquilo inferior y un grupo alquilo inferior substituido por halogeno como substituyente, (28) un grupo carbamoilo que puede tener un grupo seleccionado del grupo que consiste de grupos (i) a (lxxviii) a continuacion como substituyente: (i) un grupo alquilo inferior, (ii) un grupo alcoxilo inferior, (iii) un grupo hidroxialquilo inferior, (iv) un grupo alcoxilo inferior alquilo inferior, (v) un grupo ariloxialquilo inferior, (vi) un grupo alquilo inferior substituido por halogeno, (vii) un grupo amino alquilo inferior que puede tener un grupo seleccionado del grupo que consiste de un grupo alquilo inferior, un grupo alcanoilo inferior, un grupo aroilo y un grupo carbamoilo group, (viii) un grupo cicloalquilo C3- 8 que puede tener un grupo seleccionado del grupo que consiste de un grupo alquilo, un grupo hidroxilo, un grupo alcoxicarbonilo inferior y un grupo fenilalcoxilo inferior como substituyente, (ix) un grupo cicloalquilo C3-8 substituido por un grupo alquilo inferior, (x) un grupo alquenilo inferior, (xi) un grupo carbamoilalquilo inferior que puede tener grupo(s) seleccionado(s) del grupo que consiste de un grupo alquilo inferior, un grupo fenilo que puede tener grupo(s) alquilo inferior y grupo(s) fenilo que pueden tener grupo(s) alcoxilo inferior como substituyente, (xii) un grupo alquilo inferior alcoxicarbonilo inferior, (xiii) un grupo furilalquilo inferior (que puede tener grupo(s) alquilo inferior como substituyente) en el grupo furilo, (xiv) un grupo tetrahidrofurilalquilo inferior, (xv) un grupo 1,3-dioxolanilalquilo inferior, (xvi) un grupo tetrahidropiranilalquilo inferior, (xvii) un grupo pirrolilalquilo inferior (que puede tener grupo(s) alquilo inferior como substituyente en el grupo pirrolilo), (xviii) un grupo alquilo inferior substitutido con un grupo dihidropirazolilo que puede tener grupo(s) oxo, (xix) un grupo pirazolilalquilo inferior (que puede tener grupo(s) alquilo inferior como substituyente en el grupo pirazolilo), (xx) un grupo imidazolilalquilo inferior, (xxi) un grupo piridilalquilo inferior, (xxii) un grupo pirazinilalquilo inferior (que puede tener grupo(s) alquilo inferior como substituyente en el grupo pirazinilo), (xxiii) un grupo pirrolidinilalquilo (que puede tener grupo(s) seleccionado(s) del grupo que consiste de grupo(s) oxo y un grupo alquilo inferior como substituyente en el grupo pirrolidinilo), (xxiv) un grupo piperidilalquilo inferior (que puede tener grupo(s) seleccionado(s) del grupo que consiste de un grupo benzoilo y un grupo alcanoilo inferior como substituyente en el grupo piperidilo), (xxv) un grupo piperazinilalquilo inferior (que puede tener grupo(s) alquilo inferior como substituyente en el grupo piperazinilo), (xxvi) un grupo morfolinilalquilo inferior, (xxvii) un grupo tienilalquilo inferior (que puede tener grupo(s) alquilo inferior como substituyente en el grupo tienilo), (xxviii) un grupo tiazolilalquilo inferior, (xxix) un grupo dihidrobenzofurilalquilo inferior, (xxx) un grupo benzopiranilalquilo inferior (que puede tener grupo(s) oxo como substituyente en el grupo benzopiranilo), (xxxi) un grupo benzimidazolilalquilo inferior, (xxxii) un grupo indolilalquilo inferior (que puede tener grupo(s) alcoxicarbonilo inferior en el grupo alquilo), (xxxiii) un grupo imidazolilalquilo inferior que tiene substituyente(s) seleccionado(s) del grupo que consiste de un grupo carbamoilo group y un grupo alcoxicarbonilo inferior en el grupo alquilo, (xxxiv) un grupo piridilo que puede tener grupo(s) seleccionado del grupo que consiste de un grupo alquilo inferior, un grupo alcoxilo y un grupo alquilo inferior alquiltioinferior alquilo como un substituyente, (xxxv) un grupo pirrolidinilo que puede tener un grupo seleccionado del grupo que consiste de un grupo alquilo inferior, un grupo alcoxicarbonilo inferior, un grupo alcanoilo inferior y un grupo aroilo como un substituyente, (xxxvi) un grupo piperidilo que puede tener grupo(s) seleccionado del grupo que consiste de un grupo alquilo inferior, un grupo alcoxicarbonilo inferior, un grupo alcanoilo inferior y un grupo aroilo que puede tener grupo(s) seleccionado del grupo que consiste de un grupo alquilo inferior y un átomo de halogeno como substituyente, (xxxvii) un grupo tetrahidrofurilo que puede tener grupo(s) oxo, (xxxviii) un grupo hexahidroazepinilo que puede tener grupo(s) oxo, (xxxix) un grupo pirazolilo que puede tener grupo(s) group (s) seleccionado(s) del grupo que consiste de un grupo alquilo, un grupo arilo y un grupo furilo como un substituyente, (xl) un grupo tiazolilo, (xli) un grupo tiadiazolilo que puede tener grupo(s) alquilo inferior, (xlii) un grupo isoxazolilo que puede tener grupo(s) alquilo inferior, (xliii) un grupo indazolilo, (xliv) un grupo indolilo, (xlv) un grupo tetrahidrobenzotiazolilo, (xlvi) un grupo tetrahidroquinolilo que puede tener grupo(s) seleccionado(s) del grupo que consiste de un grupo alquilo inferior, un grupo alcoxiloinferior, un átomo de halogeno y un grupo oxo como un substituyente, (xlvii) un grupo quinolilo que puede tener grupo(s) alquilo inferior, (xlviii) un grupo benzodioxolilalquilo inferior, (xlix) un grupo arilo que puede tener grupo(s) como substituyente, seleccionado del grupo que consiste de un átomo de halogeno; un grupo alquilo inferior; un grupo alcoxiloinferior; un grupo alquilo inferior substituido por halogeno; un grupo alcoxilo inferior substituido por halogeno; un grupo alquenilo inferior; un grupo amino que puede tener un grupo seleccionado del grupo que consiste de un grupo alcanoilo inferior, un grupo sulfonilalquilo inferior, un grupo alquilo inferior y un grupo arilo; un grupo sulfamoilo; un grupo alquiltio inferior; un grupo alcanoilo inferior ; un grupo alcoxicarbonilo inferior; un grupo pirrolilo; un grupo alquinilo inferior; un grupo ciano; un grupo nitro; un grupo ariloxilo; un grupo arilalcoxilo inferior; un grupo hidroxilo; un grupo hidroxialquilo inferior; un grupo carbamoilo que puede tener un grupo seleccionado del grupo que consiste de un grupo alquilo inferior y un grupo arilo; un grupo pirazolilo; un grupo pirrolidinilo que puede tener grupo(s) oxo; un grupo oxazolilo; un grupo imidazolilo que puede tener grupo(s) alquilo inferior; un grupo dihidrofurilo que puede tener grupo(s) oxo; un grupo tiazolidi
ARP060103780A 2005-08-31 2006-08-30 Derivados de benzotiofeno con propiedades antipsicoticas AR055203A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005251055 2005-08-31

Publications (1)

Publication Number Publication Date
AR055203A1 true AR055203A1 (es) 2007-08-08

Family

ID=37709698

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103780A AR055203A1 (es) 2005-08-31 2006-08-30 Derivados de benzotiofeno con propiedades antipsicoticas

Country Status (26)

Country Link
US (3) US8071600B2 (es)
EP (4) EP1919907B9 (es)
JP (1) JP4785677B2 (es)
KR (2) KR101008873B1 (es)
CN (4) CN102702182A (es)
AR (1) AR055203A1 (es)
AT (4) ATE557022T1 (es)
AU (2) AU2006285607B2 (es)
BR (1) BRPI0615140A2 (es)
CA (1) CA2620688C (es)
CY (1) CY1111671T1 (es)
DE (1) DE602006020294D1 (es)
DK (1) DK1919907T5 (es)
ES (4) ES2382445T3 (es)
HK (1) HK1119707A1 (es)
IL (1) IL189383A (es)
MX (1) MX2008002736A (es)
MY (1) MY145670A (es)
PL (1) PL1919907T3 (es)
PT (1) PT1919907E (es)
RU (1) RU2415854C2 (es)
SG (1) SG155180A1 (es)
SI (1) SI1919907T1 (es)
TW (1) TWI329641B (es)
WO (1) WO2007026959A2 (es)
ZA (1) ZA200801888B (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101157272B1 (ko) 2003-07-22 2012-06-15 아레나 파마슈티칼스, 인크. 5?ｈｔ2ａ 세로토닌 수용체의 조절자로서 이와 관련된질환의 예방 및 치료에 유용한 디아릴 및 아릴헤테로아릴우레아 유도체
SA05260357B1 (ar) 2004-11-19 2008-09-08 ارينا فارماسيتو تيكالز ، أنك مشتقات 3_فينيل_بيرازول كمعدلات لمستقبل سيروتينين 5_ht2a مفيدة في علاج الاضطرابات المتعلقه به
MX2008013400A (es) 2006-04-19 2008-11-10 Astellas Pharma Inc Derivado de azolcarboxamida.
CN104761498B (zh) 2006-05-18 2017-12-26 艾尼纳制药公司 5‑ht2a血清素受体的调节剂
US8481535B2 (en) 2006-05-18 2013-07-09 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor
WO2007136703A1 (en) 2006-05-18 2007-11-29 Arena Pharmaceuticals, Inc. Primary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
TWI329102B (en) * 2006-08-15 2010-08-21 Nat Health Research Institutes Thiourea compounds and method for inhibiting hepatitis c virus infection
WO2008020306A2 (en) * 2006-08-18 2008-02-21 Pfizer Products Inc. Isoindole derivatives
TWI415845B (zh) 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
US20080186971A1 (en) * 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
EP1972628A1 (en) * 2007-03-21 2008-09-24 Schwarz Pharma Ag Indolizines and aza-analog derivatives thereof as CNS active compounds
WO2008124300A1 (en) * 2007-04-10 2008-10-16 National Health Research Institutes Hepatitis c virus inhibitors
EP2155689B1 (en) 2007-05-31 2015-07-08 Boehringer Ingelheim International GmbH Ccr2 receptor antagonists and uses thereof
US7897764B2 (en) * 2007-06-08 2011-03-01 National Health Research Institutes Thiourea derivatives
WO2009006437A1 (en) * 2007-06-29 2009-01-08 Emory University Nmda receptor antagonists for neuroprotection
JP5393677B2 (ja) 2007-08-15 2014-01-22 アリーナ ファーマシューティカルズ， インコーポレイテッド ５−ＨＴ２Ａセロトニン受容体に関連した障害の治療のための５−ＨＴ２Ａセロトニン受容体のモジュレーターとしてのイミダゾ［１，２−ａ］ピリジン誘導体
JPWO2009025265A1 (ja) * 2007-08-21 2010-11-25 塩野義製薬株式会社 ピペラジン誘導体
AU2008314922B2 (en) 2007-10-24 2013-08-29 Astellas Pharma Inc. Azolecarboxamide compound or salt thereof
WO2009058729A2 (en) * 2007-10-29 2009-05-07 Schering Corporation Thiazole carboxamide derivatives and their to treat cancer
EP2254884B1 (en) * 2008-02-15 2013-05-01 F. Hoffmann-La Roche AG 3-alkyl-piperazine derivatives and uses thereof
JP5355582B2 (ja) 2008-02-22 2013-11-27 大塚製薬株式会社 ベンゾジアゼピン化合物及び医薬組成物
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US8198284B2 (en) * 2008-04-30 2012-06-12 National Health Research Institutes Treatment of neurodegenerative disorders with thiourea compounds
KR20110016891A (ko) * 2008-05-09 2011-02-18 에모리 유니버시티 신경정신 장애의 치료를 위한 ｎｍｄａ 수용체 길항물질
KR20110028661A (ko) 2008-07-15 2011-03-21 노파르티스 아게 Ｄｇａｔ１ 억제제로서의 헤테로아릴 유도체
JP2011529090A (ja) * 2008-07-28 2011-12-01 江蘇国華投資有限公司 アラルキルピペリジン（又はピペラジン）誘導体及びその統合失調症治療のための使用
BRPI0917704A2 (pt) * 2008-09-01 2016-02-16 Neurosearch As composto, composição farmacêutica, e, uso de um composto químico
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
CN109438352A (zh) 2008-10-28 2019-03-08 艾尼纳制药公司 治疗5-ht2a5-羟色胺受体相关障碍的5-ht2a5-羟色胺受体调节剂组合物
CN103724328B (zh) 2008-12-19 2015-10-14 贝林格尔.英格海姆国际有限公司 作为ccr2受体拮抗剂用于治疗炎症、哮喘和copd的环状嘧啶-4-甲酰胺
US8748623B2 (en) * 2009-02-17 2014-06-10 Syntrix Biosystems, Inc. Pyridinecarboxamides as CXCR2 modulators
RU2553676C2 (ru) 2009-08-21 2015-06-20 Оцука Фармасьютикал Ко., Лтд. СПОСОБ ПОЛУЧЕНИЯ ПРОИЗВОДНОГО БЕНЗО[b][1,4]ДИАЗЕПИН-2,4-ДИОНА
TWI481601B (zh) * 2009-08-21 2015-04-21 Otsuka Pharma Co Ltd 含氮化合物及藥學組成物
MX2012006964A (es) 2009-12-17 2012-07-17 Boehringer Ingelheim Int Nuevos antagonistas del receptor ccr2 y usos de los mismos.
US8980891B2 (en) 2009-12-18 2015-03-17 Arena Pharmaceuticals, Inc. Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
WO2011109679A2 (en) * 2010-03-05 2011-09-09 Amira Pharmaceuticals, Inc. Inhibitors of 5-lipoxygenase
EP2569298B1 (en) 2010-05-12 2015-11-25 Boehringer Ingelheim International GmbH Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
US8946218B2 (en) 2010-05-12 2015-02-03 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments
JP5647339B2 (ja) 2010-05-17 2014-12-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ２アンタゴニスト及びこれらの使用
US9018212B2 (en) 2010-05-25 2015-04-28 Boehringer Ingelheim International Gmbh Pyridazine carboxamides as CCR2 receptor antagonists
EP2576538B1 (en) 2010-06-01 2015-10-28 Boehringer Ingelheim International GmbH New CCR2 antagonists
CA2811990C (en) 2010-08-23 2023-03-21 Dean Y. Maeda Aminopyridine- and aminopyrimidinecarboxamides as cxcr2 modulators
CN102206214B (zh) * 2011-04-07 2014-03-12 华中科技大学 苯并吡喃酮类衍生物及其应用
EP2731941B1 (en) 2011-07-15 2019-05-08 Boehringer Ingelheim International GmbH Novel and selective ccr2 antagonists
AR088352A1 (es) * 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
WO2013169964A1 (en) * 2012-05-09 2013-11-14 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
EP2925321A4 (en) * 2012-11-27 2016-04-27 Merck Sharp & Dohme 2-pyridylamino-4-nitrile-piperidinyl orexin receptor antagonists
US9745284B2 (en) * 2013-03-08 2017-08-29 Merck Sharp & Dohme Corp. 2-pyridyloxy-4-ether orexin receptor antagonists
WO2014152013A1 (en) * 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York 4-phenylpiperidines, their preparation and use
CN104059046B (zh) * 2013-03-18 2017-02-08 江苏恩华药业股份有限公司 黄酮类衍生物及其应用
CN104447723A (zh) * 2014-11-28 2015-03-25 瑞阳制药有限公司 7-(4-(4-(苯并[b]噻吩基)-1-哌嗪基)丁氧基)-2(1H)-喹啉酮的制备方法
JP2018516992A (ja) 2015-06-12 2018-06-28 アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
EP3317270B1 (en) 2015-07-02 2020-05-13 Centrexion Therapeutics Corporation (4-((3r,4r)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2r,6s)-6-(p-tolyl)tetrahydro-2h-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate
WO2017011767A2 (en) 2015-07-15 2017-01-19 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
CN106749219A (zh) 2015-11-20 2017-05-31 江苏恩华药业股份有限公司 一种内酰胺类衍生物及其应用
EP3397636B1 (en) 2015-12-28 2021-08-04 Honour (R&D) Process for the preparation of quinoline-2(1h)-one derivatives
CN112079812B (zh) * 2020-09-29 2021-08-06 浙江大学 哌唑类抗精神病药物关键中间体及其电还原方法
CN112125896B (zh) * 2020-09-29 2021-10-29 湖南省湘中制药有限公司 一种抗精神病药依匹哌唑电化学制备方法
TW202233602A (zh) * 2020-10-27 2022-09-01 美商艾尼納製藥公司 可用於治療5-ht2a血清素受體相關疾病之作為5-ht2a血清素受體調節劑之嘧啶衍生物
CN115772175A (zh) * 2021-09-07 2023-03-10 中国科学院分子细胞科学卓越创新中心 噻吩并环化合物及其制备方法和应用
MX2024009077A (es) 2022-01-29 2024-09-30 Suven Life Sciences Ltd Compuestos de benzotiazol y benzoisoxazola para el tratamiento de trastornos mentales.
CN115521298A (zh) * 2022-05-09 2022-12-27 江苏慧聚药业股份有限公司 依匹哌唑的制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0005828B1 (de) * 1978-06-06 1981-03-11 Hoechst Aktiengesellschaft Neue substituierte Phenylpiperazinderivate, diese enthaltende Arzneimittel und Verfahren zu deren Herstellung
JPS5649361A (en) 1979-09-28 1981-05-02 Otsuka Pharmaceut Co Ltd Carbostyril derivative
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US4883795A (en) * 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
NZ231631A (en) * 1988-12-08 1992-07-28 Duphar Int Res Heterocyclically-substituted piperazine and diazepine derivatives and anxiolytic compositions
WO1991000863A1 (en) 1989-07-07 1991-01-24 Pfizer Inc. Heteroaryl piperazine antipsychotic agents
CA2067475C (en) 1991-05-08 2000-10-10 Yasuo Oshiro Carbostyril derivatives and their use
US5240927A (en) * 1992-05-19 1993-08-31 Hoechst-Roussel Pharmaceuticals Incorporated Benzo[β]thiophen-3-yl piperazines as antipsychotic agents
US5576321A (en) 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
DE69618050T2 (de) 1995-03-17 2002-07-11 Aventis Pharmaceuticals Inc., Cincinnati Substituierte Benzylthienylpiperazine, ihre Anwendung als Arzneimittel und Verfahren für ihre Herstellung
FR2740134B1 (fr) 1995-10-18 1998-01-09 Pf Medicament Derives d'amines cycliques d'aryl-piperazines, leur preparation et les compositions pharmaceutiques les contenant
WO1998007703A1 (fr) 1996-08-22 1998-02-26 Meiji Seika Kaisha, Ltd. Derives quinoleine et agent psychotrope
FR2761068B1 (fr) 1997-03-20 1999-04-23 Synthelabo Derives de piperazin-4-ylthieno[3,2-c]pyridin-4-yl-2- carboxamide, leur preparation et leur application en therapeutique
IL146564A0 (en) 1999-05-24 2002-07-25 Mitsubishi Pharma Corp Phenoxypropylamine derivatives and pharmaceutical compositions containing the same
AR027134A1 (es) * 1999-12-30 2003-03-12 Lundbeck & Co As H Derivados de indol.
AR027133A1 (es) * 1999-12-30 2003-03-12 Lundbeck & Co As H Derivados de heteroarilo, su preparacion y uso.
JP4497815B2 (ja) 2001-02-16 2010-07-07 アベンティス・ファーマスーティカルズ・インコーポレイテツド 新規な複素環式アミド誘導体およびドーパミンｄ３受容体リガンドとしてのその使用
WO2002098367A2 (en) * 2001-06-07 2002-12-12 Wayne State University Hybrid 2-aminotetralin and aryl-substituted piperazine compounds and their use in altering cns activity
US7342015B2 (en) * 2001-06-29 2008-03-11 H. Lundbeck A/S Indole derivatives
OA12923A (en) 2002-09-17 2006-10-13 Warner Lambert Co Heterocyclic substituted piperazines for the treatment of schizophrenia.
WO2004029048A1 (en) 2002-09-26 2004-04-08 Warner-Lambert Company Llc Heterocyclic substituted piperazines for the treatment of schizophrenia
GB0227240D0 (en) * 2002-11-21 2002-12-31 Glaxo Group Ltd Compounds
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
JP4315393B2 (ja) * 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物

Also Published As

Publication number Publication date
EP1919907A2 (en) 2008-05-14
US20120028920A1 (en) 2012-02-02
EP2284169B1 (en) 2012-03-14
DK1919907T5 (da) 2011-09-12
KR20100063807A (ko) 2010-06-11
ZA200801888B (en) 2009-07-29
CN102850336A (zh) 2013-01-02
BRPI0615140A2 (pt) 2010-01-12
EP2284169A1 (en) 2011-02-16
CN102558140A (zh) 2012-07-11
HK1119707A1 (en) 2009-03-13
CA2620688C (en) 2014-03-25
EP2287161A1 (en) 2011-02-23
AU2006285607B2 (en) 2010-02-25
EP2287162B1 (en) 2012-05-09
AU2006285607A1 (en) 2007-03-08
ES2383948T3 (es) 2012-06-27
CN101258147A (zh) 2008-09-03
ATE557022T1 (de) 2012-05-15
IL189383A (en) 2013-03-24
JP2007091733A (ja) 2007-04-12
DE602006020294D1 (de) 2011-04-07
ATE549330T1 (de) 2012-03-15
ES2383949T3 (es) 2012-06-27
WO2007026959A2 (en) 2007-03-08
CA2620688A1 (en) 2007-03-08
ES2382445T3 (es) 2012-06-08
US20140031334A1 (en) 2014-01-30
TW200800937A (en) 2008-01-01
EP1919907B1 (en) 2011-02-23
JP4785677B2 (ja) 2011-10-05
CN101258147B (zh) 2012-03-21
CY1111671T1 (el) 2015-10-07
PL1919907T3 (pl) 2011-07-29
IL189383A0 (en) 2008-06-05
KR20080033446A (ko) 2008-04-16
RU2008112224A (ru) 2009-10-10
AU2010200362A1 (en) 2010-02-18
CN102702182A (zh) 2012-10-03
MX2008002736A (es) 2008-03-26
EP1919907B9 (en) 2012-01-18
WO2007026959A3 (en) 2007-08-16
TWI329641B (en) 2010-09-01
ES2362961T3 (es) 2011-07-15
MY145670A (en) 2012-03-15
EP2287161B1 (en) 2012-05-09
EP2287162A1 (en) 2011-02-23
SG155180A1 (en) 2009-09-30
ATE499369T1 (de) 2011-03-15
ES2362961T9 (es) 2012-02-13
ATE557021T1 (de) 2012-05-15
DK1919907T3 (da) 2011-04-18
KR101008873B1 (ko) 2011-01-19
PT1919907E (pt) 2011-03-23
RU2415854C2 (ru) 2011-04-10
US8598162B2 (en) 2013-12-03
SI1919907T1 (sl) 2011-05-31
US20090264404A1 (en) 2009-10-22
US8071600B2 (en) 2011-12-06

Similar Documents

Publication Publication Date Title
AR055203A1 (es) Derivados de benzotiofeno con propiedades antipsicoticas
RU2405771C2 (ru) Гетероциклические замещенные фенилметаноны в качестве ингибиторов переносчика глицина 1
ES2406089T3 (es) Pirazolpirimidinas sustituidas
Al-Issa Synthesis and anticancer activity of some fused pyrimidines and related heterocycles
Abbas et al. Synthesis, antitumor and antibacterial activities of some novel tetrahydrobenzo [4, 5] thieno [2, 3-d] pyrimidine derivatives
CO5700817A2 (es) Compuesto pentaciclico heteroaromatico y uso medicinal del mismo
US6503937B1 (en) Oxobenzofuranylide-dihydroindolone
AU2006204917A1 (en) Indole derivatives for treating viral infections
NZ508765A (en) Beta-carboline derivatives and pharmaceuticals thereof that selectively bind somatostatin receptor subtypes
DK1178982T3 (da) Heterocykliske, substituerede aminoazacykliske forbindelser, der er nyttige som midler til centralnervesystemet
WO2006041773A2 (en) Lactam compounds useful as protein kinase inhibitors
AR054191A1 (es) Compuestos de 3 aminopirrolidina sustituidos utiles como inhibidores de la recaptacion de monoamina
CA2946702C (en) Bicyclic or tricyclic heterocyclic compound
Chen et al. Synthesis of 2-substituted-3-(1 H-indol-3-yl) isoindolin-1-one derivatives in water under catalyst-free conditions
MX2009006650A (es) Pirimidinas substituidas que contienen una porcion heteroarilamida o heteroarilfenilo.
PE20081458A1 (es) DERIVADOS DE PIRIDO[2,3-b]INDOL COMO INHIBIDORES DE QUINASAS
Verbitskiy et al. Assembly of annulated 1, 3-diazapyrenes by consecutive cross-coupling and cyclodehydrogenation of (het) arene moieties
Sarkar et al. Synthesis and photophysics of selective functionalized π-conjugated, blue light emitting, highly fluorescent C7-imidazo indolizine derivatives
Brandner et al. Multicomponent synthesis of chromophores–The one-pot approach to functional π-systems
WO2009022738A1 (ja) 着色組成物、インクジェット記録用インクおよびヘテロ環化合物
ATE515540T1 (de) Trisazofarbstoffe mit pyrazolylendgruppe und ihre verwendung im farbstrahldruck
Nayak et al. Synthesis, characterization, DFT and photophysical studies of new class of 1, 3, 4-oxadiazole-isobenzofuran hybrids
ATE412038T1 (de) Tintenstrahltinte
Karpenko et al. Experimental and theoretical spectroscopic study of thione-thiol tautomerism of new hybrides 1, 3, 4-oxadiazole-2-thion with acridine-9 (10h)-one
Abdel Hamid et al. Synthesis and fluorescent properties of some Furan‐tagged Thieno [2, 3‐d] pyrimidines and Thieno [2, 3‐d: 4, 5‐d'] dipyrimidines

Legal Events

Date Code Title Description
FB Suspension of granting procedure